Research
Energy balance
These therapies may reduce the risk for HF hospitalizations.
Incorporating these therapies may help reduce hospital admissions for heart failure in this patient population.
StrongSupportsmedium confidence
Some evidence also suggests that these therapies may reduce risk for HF hospitalizations.
Why this rating
Based on results from randomized clinical trials.
Source
Advances in the management of obesity and heart failure: latest evidence from clinical trials
Thomaz Alexandre Costa et al. · Current Opinion in Cardiology · 2025
DOI 10.1097/hco.0000000000001214
reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Incretin-based therapies, including GLP-1 receptor agonists like semaglutide and tirzepatide, can improve quality of life, exercise tolerance, and markers of HF severity while promoting weight loss in patients with obesity and HFpEF.Strong
- Finerenone has been associated with reduced cardiovascular mortality and total worsening HF events across all BMI levels, with greater benefits observed in patients with higher BMIs.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →